Recent treatment and prognosis in 643 patients with extramammary Paget's disease.

Information about extramammary Paget's (EMPD) treatment is limited because of the rarity of the disease. The prognosis differs between in situ EMPD and invasive EMPD; therefore, therapy should be planned according to the disease stage. We collected data on 643 EMPD cases treated between 2015 and 2019 in Japan and assessed recent trends in EMPD treatment and prognosis based on the EMPD‐oriented TNM staging. Among the 643 patients, 317 had stage 0 (49.3%), 185 had stage I (28.8%), 51 had stage II (7.9%), 18 had stage IIIA (2.8%), 48 had stage IIIB (7.5%) and 24 had stage IV (3.7%) disease. Each stage showed a distinct survival curve, with the exception of stages II and IIIA. Curative surgery was most common in patients with stage 0–III disease. Chemotherapy was the first‐line therapy, mainly in patients with stage IIIB and IV disease, most commonly with docetaxel (DTX), followed by DTX + tegafur gimeracil oteracil potassium (TS‐1) and TS‐1. Patients with local disease exhibited a 4.4% recurrence rate. Univariate analysis revealed no prognostic differences according to age, sex or primary tumour site. SLNB was not related to disease‐specific survival. In multivariate analysis, female sex significantly predicted local relapse in stage 0–I (HR 3.09; 95% CI, 1.13–8.43), and initial treatment with curative surgery was significantly protective in terms of disease‐specific survival in stage II–IIIA (HR, 0.17; 95% CI, 0.04–0.71) and stage IIIB–IV (HR 0.16; 95% CI, 0.05–0.51). Further clinical studies are needed to improve the prognosis of patients with stage II–IV EMPD. [ABSTRACT FROM AUTHOR]